Denosumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Denosumab: From Osteoporosis to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Denosumab is a RANKL-inhibiting monoclonal antibody, originally used to treat osteoporosis (including postmenopausal and drug-induced osteoporosis). The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy (top-ranked prediction), but no clinical trials and no publications currently support this specific direction. Among the other top predictions, only dermatitis has any supporting material (1 Phase 1 mechanistic study and several case reports, mostly describing skin adverse events).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Osteoporosis, postmenopausal osteoporosis, drug-induced osteoporosis (approved indication text is not available in the Singapore licence records) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, denosumab is a human monoclonal antibody that binds RANKL (receptor activator of nuclear factor κB ligand) and thereby inhibits osteoclast-mediated bone resorption. Its efficacy in osteoporosis is established.
For severe nonproliferative diabetic retinopathy, the link is speculative. RANKL/OPG signalling has been discussed in vascular and inflammatory pathways, which could in theory be relevant to diabetic microvascular disease. However, none of the data compiled for this report supports this link, and the prediction rests on the model score alone.
The second-ranked prediction, diabetic retinopathy (score 99.23%), has two indirect publications. One is a real-world cohort study with a meta-analysis suggesting denosumab may be associated with a lower incidence of type 2 diabetes and fewer foot ulcers and deaths compared with bisphosphonates. The other is a fracture-risk assessment study in type 2 diabetes. Neither tests denosumab against retinopathy, so both are hypothesis-generating at best.
Clinical Trial Evidence
For the top-ranked prediction (severe nonproliferative diabetic retinopathy), currently no related clinical trials are registered.
For reference, the only trial found across the top predictions is for dermatitis (rank 3):
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01978483 | Phase 1 | Completed | 31 | Effect of RANKL inhibition on UV-induced immunosuppression. A mechanistic study, not in dermatitis patients, and it does not assess clinical efficacy |
Literature Evidence
For the top-ranked prediction (severe nonproliferative diabetic retinopathy), currently no related literature is available.
The most relevant publications for the next-ranked predictions are listed below (indirect evidence only):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38899553 | 2024 | Cohort + meta-analysis | Diabetes Obes Metab | Denosumab vs bisphosphonates: real-world data on type 2 diabetes incidence, diabetic complications and mortality (diabetic retinopathy) |
| 32026309 | 2020 | Cohort | Drugs Aging | Cataract surgery and AMD risk after denosumab vs zoledronic acid; general ocular outcomes, not diabetic cataract |
| 22108301 | 2011 | Review | Clin Ther | Review of denosumab for bone loss in postmenopausal osteoporosis (original indication) |
| 31890758 | 2020 | Case report | Bone Rep | First documented DRESS syndrome in response to denosumab (dermatitis) |
| 39175449 | 2024 | Case report | Acta Derm Venereol | Denosumab-induced acute generalized exanthematous pustulosis |
| 32656848 | 2021 | Case report | Clin Exp Dermatol | Two cases of lichen planus with denosumab |
| 29076163 | 2018 | Case report | J Cutan Pathol | Denosumab-induced cutaneous hypersensitivity with a lymphohistiocytic pattern |
| 30826782 | 2019 | Case report | BMJ Case Rep | c-ANCA vasculitis after starting denosumab |
Note that the dermatitis literature mainly documents skin adverse reactions to denosumab and does not support therapeutic benefit.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14116P | XGEVA Solution for Injection 120 mg/vial | Injection, solution | Not available |
| SIN14024P | Prolia Solution for Injection 60 mg/ml (Prefilled Syringe) | Injection, solution | Not available |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction screening. The ones listed are all rated Moderate, and include:
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone, methylprednisolone
- Radiopharmaceuticals and related agents: ibritumomab tiuxetan, iobenguane (I-131), tositumomab (with and without I-131)
- Immunomodulators and antimetabolites: levamisole, trimetrexate, mercaptopurine, tacrolimus, dupilumab
- Adrenocorticotropic agents: corticotropin, tetracosactide
- Cutaneous adverse events: The dermatitis literature reports AGEP, DRESS, lichenoid eruptions, erythema nodosum and vasculitis associated with denosumab, which is relevant to any repurposing toward skin conditions.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The top predictions rest almost entirely on model scores. There are no clinical trials or direct literature for severe nonproliferative diabetic retinopathy, and the evidence level is L5. The only signal found (dermatitis) is a Phase 1 mechanistic study plus case reports that mostly describe harm rather than benefit.
To proceed, the following is needed:
- Mechanism of action data and a plausible mechanistic rationale for RANKL inhibition in diabetic retinopathy
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Approved indication text for the two Singapore registrations
- Preclinical or observational studies that directly examine denosumab and retinopathy outcomes
- A review of whether the ocular-outcome cohort data (cataract, AMD) offer any relevant safety or efficacy signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.